Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights include PrognomiQ's MOSAIC study, which combines proteomics with other molecular data to improve early-stage lung cancer detection, and Salk Institute's research on Relative Energy Deficiency in Sport (REDs) affecting 40% of athletes. The presentations will demonstrate how Seer's technology enables multi-omic research at unprecedented depth, scale, and speed.
Seer presenterà il suo Proteograph Product Suite all'American Society of Human Genetics (ASHG) Annual Meeting 2024, dimostrando come la proteomica profonda migliori la ricerca genomica. L'azienda presenterà ricerche innovative su cancro ai polmoni e Malattia di Alzheimer attraverso una sessione CoLab in collaborazione con PrognomiQ e il Salk Institute.
I punti salienti includono lo studio MOSAIC di PrognomiQ, che combina la proteomica con altri dati molecolari per migliorare la rilevazione precoce del cancro ai polmoni, e la ricerca del Salk Institute sull'energia relativa inadeguata negli sport (REDs) che colpisce il 40% degli atleti. Le presentazioni dimostreranno come la tecnologia di Seer consenta ricerche multi-omiche a una profondità, scala e velocità senza precedenti.
Seer presentará su Proteograph Product Suite en la reunión anual de la American Society of Human Genetics (ASHG) 2024, demostrando cómo la proteómica profunda mejora la investigación genómica. La empresa presentará investigaciones innovadoras sobre cáncer de pulmón y enfermedad de Alzheimer a través de una sesión CoLab con PrognomiQ y el Salk Institute.
Los aspectos clave incluyen el estudio MOSAIC de PrognomiQ, que combina la proteómica con otros datos moleculares para mejorar la detección temprana del cáncer de pulmón, así como la investigación del Salk Institute sobre la Deficiencia Energética Relativa en el Deporte (REDs) que afecta al 40% de los atletas. Las presentaciones demostrarán cómo la tecnología de Seer permite investigaciones multi-ómicas con una profundidad, escala y velocidad sin precedentes.
Seer는 Proteograph Product Suite를 2024년 미국 유전자학회(ASHG) 연례 회의에서 선보이며, 심층 프로티오믹스가 유전체 연구를 어떻게 향상시키는지를 보여줄 것입니다. 이 회사는 PrognomiQ 및 Salk Institute와의 CoLab 세션을 통해 폐암 및 알츠하이머병에 대한 혁신적인 연구를 발표할 예정입니다.
주요 내용으로는 폐암 조기 발견 개선을 위한 단백질체학과 기타 분자 데이터를 결합한 PrognomiQ의 MOSAIC 연구, 그리고 40%의 운동선수에게 영향을 미치는 스포츠에서의 상대 에너지 결핍(REDs)에 대한 Salk Institute의 연구가 포함됩니다. 이 발표들은 Seer의 기술이 전례 없는 깊이, 규모, 속도로 다중 오믹스 연구를 가능하게 한다는 것을 보여줄 것입니다.
Seer présentera sa Proteograph Product Suite lors de la réunion annuelle de l'American Society of Human Genetics (ASHG) 2024, démontrant comment la protéomique approfondie améliore la recherche génomique. L'entreprise présentera des recherches novatrices sur le cancer du poumon et la maladie d'Alzheimer lors d'une séance CoLab avec PrognomiQ et le Salk Institute.
Les points clés comprennent l'étude MOSAIC de PrognomiQ, qui combine la protéomique avec d'autres données moléculaires pour améliorer la détection précoce du cancer du poumon, ainsi que les recherches du Salk Institute sur le déficit énergétique relatif dans le sport (REDs) touchant 40 % des athlètes. Les présentations montreront comment la technologie de Seer permet une recherche multi-omique d'une profondeur, d'une échelle et d'une rapidité sans précédent.
Seer wird seine Proteograph Product Suite auf dem Jahrestreffen der American Society of Human Genetics (ASHG) 2024 präsentieren und dabei demonstrieren, wie tiefe Proteomik die genomische Forschung verbessert. Das Unternehmen wird bahnbrechende Forschung zu Lungenkrebs und Alzheimer-Krankheit in einer CoLab-Sitzung mit PrognomiQ und dem Salk Institute vorstellen.
Wichtige Höhepunkte sind die MOSAIC-Studie von PrognomiQ, die Proteomik mit anderen molekularen Daten kombiniert, um die frühzeitige Erkennung von Lungenkrebs zu verbessern, und die Forschung des Salk Institute zur relativen Energiedefizienz im Sport (REDs), die 40 % der Athleten betrifft. Die Präsentationen werden zeigen, wie die Technologie von Seer mehrdimensionale Forschungsprojekte mit beispielloser Tiefe, Größe und Geschwindigkeit ermöglicht.
- Platform demonstrates capability to enhance early-stage lung cancer detection through multi-omic approach
- Technology enables breakthrough research in major disease areas (Alzheimer's, lung cancer)
- Platform shows versatility across multiple research applications and disease areas
- None.
Insights
The presented research developments, while scientifically interesting, lack immediate financial or market-moving implications for Seer (NASDAQ: SEER). The company's participation in ASHG 2024 and presentation of research findings represent routine scientific communications that are common in the biotech industry. While the Proteograph Product Suite shows promise in various applications like lung cancer detection and Alzheimer's research, no specific commercial milestones, revenue figures, or market expansion details are provided.
The collaborations with PrognomiQ and Salk Institute, while potentially valuable for future development, don't present immediate material impact on the company's financial performance. The research presentations focus on technical capabilities and potential applications rather than concrete business outcomes or market opportunities that would influence investor decisions in the near term.
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite
REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, will showcase the Proteograph Product Suite’s unique ability to deliver deep proteomic insights that complement and strengthen genomic and other “omic” research at the American Society of Human Genetics (ASHG) 2024 Annual Meeting in Denver, Colo., from Nov. 5-9. Seer will present a CoLab session exploring research breakthroughs from PrognomiQ and Salk Institute, as well as several presentations in the scientific sessions, all enabled by the industry-leading capabilities of Seer’s Proteograph Product Suite.
Covering prominent disease areas like lung cancer and Alzheimer’s Disease, as well as conditions scientists are only starting to understand, such as Relative Energy Deficiency in Sport (REDs), these sessions will explore how Seer is linking powerful proteomic capabilities at previously unattainable depth, scale, and speed, with genomic data to produce a compelling and growing body of advanced research.
“Advancements in genomic research in recent decades have significantly enhanced our understanding of biology and human health,” said Asim Siddiqui, PhD, Senior Vice President, Research and Tech Development at Seer. “With the Proteograph Product Suite, we are now able to combine deep proteomics at scale with deep genomics at scale and push the boundaries of biological insight, opening up new frontiers in scientific discovery. At Seer, we are excited to see our Proteograph Product Suite at the forefront of so many of these multi-omic breakthroughs, and we believe we are just scratching the surface of what is possible.”
Seer CoLab Session at the ASHG 2024 Annual Meeting:
The Power of Deep Proteomics: Driving the Next Generation of Genomic Research
Unleashing the Power of Multi-omics: A Breakthrough in the Early Detection of Lung Cancer
Philip Ma, PhD
CEO & Founder, PrognomiQ, Inc.
Lung cancer remains a leading cause of death globally, driven in large part by its detection only in late and advanced stages of cancer. Thus, early detection is crucial for improved outcomes, but current screening methods, such as low-dose CT scans, face limitations in adherence and sensitivity. Philip Ma and colleagues are exploring a multi-omics biomarker test that leverages the power of proteomics, transcriptomics, and metabolomics to detect early-stage lung cancer.
Their study, the MOSAIC study, employed a deep and untargeted exploration of the plasma proteome, coupled with transcriptomic and metabolomic data. This comprehensive approach enabled them to identify a panel of biomarkers that can accurately discriminate between lung cancer patients and controls, even in the early stages of the disease.
By combining multiple molecular data types, their multi-omics classifier offers a more sensitive and specific approach to lung cancer detection. This classifier demonstrated exceptional sensitivity for all-stage, stage I, and stage II-IV lung cancer, outperforming existing published studies. This breakthrough enables the development of a blood-based lung cancer detection test, with the potential to significantly improve early diagnosis, leading to better treatment outcomes and reducing mortality rates.
“To truly make a difference for the millions of patients each year who are diagnosed with lung cancer, we must find ways to detect the disease sooner when the chances of treatment and survival are more favorable,” said Philip Ma, CEO and Founder of PrognomiQ. “The work we’re doing using Seer’s Proteograph platform is enabling us to transform early lung cancer detection, giving us real hope that more lives can be saved.”
Mouse Model of Relative Energy Deficiency in Sport
Laura van Rosmalen, PhD
Satchidananda Panda Lab, Salk Institute for Biological Studies
Relative Energy Deficiency in Sport (REDs) is associated with insufficient energy intake and excessive energy expenditure. This state of low energy availability can result in systemic neuroendocrine and metabolic abnormalities affecting health and performance. Studies on mice have shown that the effects of REDs can be wide-ranging, including significant shrinkage of vital organs like the kidney and reproductive organs, deterioration of bone quality, and negative psychological consequences.
Despite the high prevalence (affecting 40 percent of athletes), little is known about how REDs impacts the body at the molecular level. This has made it difficult to understand REDs, its diagnosis and treatment, and highlights the importance of an animal model of REDs. Deep proteomic insights are helping to reveal protein signatures of REDs, with important implications for metabolic health and athletic performance.
“A multi-omics approach, including unbiased proteomics, is arguably even more important for a condition like REDs for which little is known about its diagnosis, effects, or potential treatments,” said Satchidananda Panda, PhD, Director, Wu-Tsai Human Performance Alliance at Salk Institute. “Seer’s technology allows our team to understand REDs on a cellular and molecular level, which in turn could lead to diagnostic tests and therapies to halt, reverse, or prevent it entirely.”
Highlights From Seer and Collaborators Presenting at the ASHG 2024 Annual Meeting:
- Seer
- Title: A Genome-wide Association Study of Mass Spectrometry Proteomics Using the Seer Proteograph Platform
- Presenting Author: Serafim Batzoglou, PhD
- Date & Time: Nov. 6, 2:30 - 4:30 p.m.
- Seer
- Title: Understanding the Impact of Genetic Variants on Alzheimer’s Disease With Mass Spectrometry Proteogenomics
- Presenting Author: Harendra Guturu, PhD
- Date & Time: Nov. 7, 2:30 - 4:30 p.m.
- New York University
- Title: Multi-omic Profiling in a 61-day Pig Kidney to Human Decedent Xenotransplant Reveals a Concerted Acute Rejection Immune Response
- Presenting Author: Brendan Keating, PhD
- Date & Time: Nov. 6, 11:15 a.m.
About Seer:
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
For more information, please visit booth #335 or contact us at pr@seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
What will Seer (SEER) present at ASHG 2024 Annual Meeting?
How is Seer (SEER) contributing to lung cancer research?
What research areas will Seer (SEER) showcase at ASHG 2024?
